2024
Evaluating the Health and Economic Impacts of Return-to-Work Interventions: A Modeling Study
Morgante N, Bjørnelv G, Aasdahl L, Nguyen C, Fimland M, Kunst N, Burger E. Evaluating the Health and Economic Impacts of Return-to-Work Interventions: A Modeling Study. Value In Health 2024, 28: 415-423. PMID: 39579934, DOI: 10.1016/j.jval.2024.10.3850.Peer-Reviewed Original ResearchQuality-adjusted life yearsReturn to workO-ACTReturn-to-work interventionsHealth-related quality of lifeDecision-analytic modelRates of sickness absenceHealth-related qualityCost-effectiveQuality of lifeRTW interventionsProductivity lossSickness absenceSick leaveCost-effectiveness thresholdRegistry dataHealthcare costsNorwegian guidelinesHealthcare perspectiveLife yearsSocietal perspectiveEconomic evaluationInterventionTrial outcomesPsychological disordersLong-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed TreatmentDisease courseEconomic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis
Ryckman T, Schumacher S, Lienhardt C, Sweeney S, Dowdy D, Mirzayev F, Kendall E. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis. The Lancet Global Health 2024, 12: e995-e1004. PMID: 38762299, PMCID: PMC11126367, DOI: 10.1016/s2214-109x(24)00088-3.Peer-Reviewed Original ResearchConceptsRifampin-resistant tuberculosisRifampin-susceptible tuberculosisMedium-term costsTuberculosis treatmentRifampin susceptibilityTuberculosis regimensStandard-of-care regimensCost-effective priceEstimated pricePrice thresholdsPriceDrug costsCost-neutralNovel drug combinationsStandard-of-careSouth AfricaTuberculosis treatment regimensEconomic implicationsStandard of carePatient-borne costsHigh-burden countriesCohort of adultsDecision-analytic modelShorter regimensNovel regimens
2021
Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model
Li N, Sawyer E, Maruszczyk K, Guzauskas G, Slomka M, Burke T, Martin A, O’Hara J, Stevenson M, Recht M. Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. Journal Of Medical Economics 2021, 24: 363-372. PMID: 33591884, DOI: 10.1080/13696998.2021.1891088.Peer-Reviewed Original ResearchConceptsStandard half-lifeExtended half-lifeSevere HBFactor IXHemophilia BAssociated health resource utilizationUS third-party payerFactor IX prophylaxisBleeding-related complicationsLifetime costsFixed treatmentStandard of careChronic joint damageTreatment costsSocietal perspectiveHealth resource utilizationHalf-lifeDecision-analytic modelClotting factor IXBleeding eventsTreatment paradigmTreatment optionsCongenital disorderProphylaxisLifetime horizon
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply